Differences
This shows you the differences between two versions of the page.
Both sides next revision | |||
blog:bpaddock:chronic_pain_suicidal_behavior_and_ideation_and_antiepileptic_drugs [2017/07/23 12:33] bpaddock 2016 study update | blog:bpaddock:chronic_pain_suicidal_behavior_and_ideation_and_antiepileptic_drugs [2019/12/28 14:58] | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== Chronic Pain Suicidal Behavior from Prescription Drugs ====== | ||
- | |||
- | [[http:// | ||
- | |||
- | Karen was taking this // | ||
- | |||
- | < | ||
- | Manufacturers of antiepileptic drugs (AEDs) or anticonvulsant drugs will update product labeling to include a warning about an increased risk of suicidal thoughts or actions and will develop a Medication Guide to help patients understand this risk. | ||
- | </ | ||
- | |||
- | This is the actual study frequently referenced to on Internet with no link to the original study as " | ||
- | // | ||
- | |||
- | < | ||
- | Gabapentin Receptor α2δ-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis | ||
- | |||
- | Çagla Eroglu, Nicola J. Allen, Michael W. Susman, Nancy A. O' | ||
- | |||
- | Synapses are asymmetric cellular adhesions that are critical for nervous system development and function, but the mechanisms that induce their formation are not well understood. We have previously identified thrombospondin as an astrocyte-secreted protein that promotes central nervous system (CNS) synaptogenesis. Here, we identify the neuronal thrombospondin receptor involved in CNS synapse formation as α2δ-1, the receptor for the anti-epileptic and analgesic drug gabapentin. We show that the VWF-A domain of α2δ-1 interacts with the epidermal growth factor-like repeats common to all thrombospondins. | ||
- | </ | ||
- | |||
- | ====== Interference with neuronal development ====== | ||
- | |||
- | This class of medication interferes with neuronal development at //any// age. | ||
- | Study from 2016 on prenatal development. | ||
- | |||
- | // | ||
- | |||
- | < | ||
- | ABSTRACT | ||
- | |||
- | Objective: To investigate pregnancy outcomes following maternal use of pregabalin. | ||
- | |||
- | Methods: This multicenter, | ||
- | |||
- | Results: Data were collected from 164 exposed pregnancies and 656 controls. A significantly higher major birth defect rate in the pregabalin group was observed after exclusion of chromosomal aberration syndromes, and when cases with exposure during first trimester of pregnancy were analyzed separately (7/116 [6.0%] vs 12/580 [2.1%]; odds ratio 3.0, 95% confidence interval 1.2–7.9, p = 0.03). The rate of live births was lower in the pregabalin group (71.9% vs 85.2%, p < 0.001), primarily due to a higher rate of both elective (9.8% vs 5.0%, p = 0.02) and medically indicated (5.5% vs 1.8%, p = 0.008) pregnancy terminations. In the Cox proportional cause specific hazards model, pregabalin exposure was not associated with a significantly higher risk of spontaneous abortion. | ||
- | |||
- | Conclusions: | ||
- | </ | ||
- | |||
- | {{tag> | ||
- | |||
- | |||
- | ~~DISCUSSION~~ | ||